Samsung Bioepis's Etanercept Biosimilar To Be Rolled Out In Europe
This article was originally published in Scrip
Samsung Bioepis Co. Ltd. has received a marketing approval from the European Commission for its biosimilar version of Amgen Inc.'s Enbrel (etanercept), the first etanercept biosimilar to be approved by the Commission and therefore likely the first to debut in Europe. But Sandoz is close behind – the Swiss company's biosimilar etanercept was accepted by review by European regulators in December 2015.
Register for our free email digests: